Page last updated: 2024-09-05

lapatinib and Exanthem

lapatinib has been researched along with Exanthem in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ayanoglu, BT; Demirdag, HG; Yalici-Armagan, B1
Dranitsaris, G; Lacouture, ME1
Agbor-Tarh, D; Azim, HA; Boyle, F; Bradbury, I; Campbell, C; de Azambuja, E; Dueck, AC; Gomez, H; Huang, Y; Jackisch, C; Lang, I; Perez, EA; Piccart, M; Pritchard, KI; Smith, I; Sonnenblick, A; Untch, M; Wolff, AC; Xu, B1
Gao, B; Guo, L; Hao, S; Hu, C; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, G; Zhang, S; Zhang, X; Zhao, J1
Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW1
Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Gilbertson, RJ; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF1
Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ1
Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY1
Berrier, A; Biswas-Baldwin, N; Compton, N; de Mendoza, FH; El-Hariry, I; Fayette, J; Franklin, N; Harrington, K; Housset, M; Kumar, R; Lau, M; Legenne, P; Mehanna, H; Remenar, E; Robinson, M1

Reviews

2 review(s) available for lapatinib and Exanthem

ArticleYear
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome; Withholding Treatment

2017
Analysis of dermatologic events in patients with cancer treated with lapatinib.
    Breast cancer research and treatment, 2009, Volume: 114, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome

2009

Trials

5 trial(s) available for lapatinib and Exanthem

ArticleYear
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
    Breast cancer research and treatment, 2014, Volume: 147, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms

2014
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome

2016
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-20, Volume: 28, Issue:27

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diarrhea; ErbB Receptors; Exanthema; Fatigue; Female; Humans; Infant; Lapatinib; Male; Maximum Tolerated Dose; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Steroids; Treatment Outcome; United States; Young Adult

2010
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
    Chinese journal of cancer, 2011, Volume: 30, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction

2011
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm Staging; Papillomaviridae; Quinazolines; Radiotherapy Dosage; Treatment Outcome

2013

Other Studies

2 other study(ies) available for lapatinib and Exanthem

ArticleYear
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Cutaneous and ocular toxicology, 2019, Volume: 38, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Panitumumab; Pruritus; Retrospective Studies

2019
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult

2010